Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04643379
Title Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Washington University School of Medicine
Indications

head and neck squamous cell carcinoma

oral squamous cell carcinoma

hypopharynx cancer

laryngeal squamous cell carcinoma

oropharynx cancer

Therapies

Carboplatin + Olaparib + Pembrolizumab

Olaparib + Pembrolizumab

Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
Washington University School of Medicine Recruiting Saint Louis Missouri 63110 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field